Since its introduction to genome editing, CRISPR-Cas9 has been used to generate cell and animal models of disease, investigate relations between genomes and phenotypes, and interfere with disease development. Although most of its applications have been in basic research, efforts are underway to move CRISPR-Cas9 from bench to bedside. This review summarizes current and prospective applications of the CRISPR-Cas9 system in biomedical and translational research on solid tumors, as well as the challenges of expanding this technology into clinical use.
Get full access to this article
View all access options for this article.
References
1.
HsuP, LanderES, ZhangF. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell, 2014; 157:1262–1278. DOI: 10.1016/j.cell.2014.05.010.
2.
YiL, LiJ. CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. Biochim Biophys Acta, 2016; 1866:197–207. DOI: 10.1016/j.bbcan.2016.09.002.
3.
LuX, XueH, KeZ, ChenJ, et al.CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet, 2015; 52:289–296. DOI: 10.1136/jmedgenet-2014-102968.
4.
SuS, HuB, ShaoJ, et al.CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep, 2016; 6:2007–0. DOI: 10.1038/srep20070.
5.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012; 12:252–264. DOI: 10.1038/nrc3239.
6.
DongH, StromeSE, SalomaoDR, et al.Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002; 8:793–800. DOI: 10.1038/nm730.
7.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012; 337:816–821. DOI: 10.1126/science.1225829.
8.
HsuPD, ScottDA, WeinsteinJA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol, 2013; 31:827–832. DOI: 10.1038/nbt.2647.
9.
KooT, LeeJ, KimJS. Measuring and reducing off-target activities of programmable nucleases including CRISPR-Cas9. Mol Cells, 2015; 38:475–481. DOI: 10.14348/molcells.2015.0103.
10.
HanahanD, WeinbergRA. The hallmarks of cancer. Cell, 2000; 100:57–70. DOI: 10.1016/S0092-8674(00)81683-9.
11.
HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell, 2011; 144:646–674. DOI: 10.1016/j.cell.2011.02.013.
12.
MitelmanF, JohanssonB, MertensF. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer, 2007; 7:233–245. DOI: 10.1038/nrc2091.
13.
PlattRJ, ChenS, ZhouY, et al.CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell, 2014; 159:440–455.
14.
MaddaloD, ManchadoE, ConcepcionCP, et al.In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR-Cas9 system. Nature, 2014; 516:423–427. DOI: 10.1038/nature13902.
15.
LiuF, ZhangY, LuM, et al.Nestin serves as a promising prognostic biomarker in non-small cell lung cancer. Am J Transl Res, 2017; 9:1392–1401.
16.
HyakusokuH, SanoD, TakahashiH, et al.JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma. J Exp Clin Cancer Res, 2016; 35:6. DOI:10.1186/s13046-016-0284-4.
17.
XuK, ChenG, LiX, et al.MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep, 2017; 7:4171–8. DOI: 10.1038/srep41718.
18.
CyranoskiD. CRISPR gene editing tested in a person for the first time. Nature, 2016; 539:47–9. DOI: 10.1038/nature.2016.20988.
IwaiY, HamanishiJ, ChamotoK, et al.Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci, 2017; 24:2–6. DOI: 10.1186/s12929-017-0329-9.
25.
Couzin-FrankelJ. Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013; 342:1432–1433. DOI: 10.1126/science.342.6165.1432.
26.
YuenK, ChanC, WongNH, et al.CRISPR-Cas9-mediated genome editing of Epstein–Barr virus in human cells. J Gen Virol, 2015; 96:626–636. DOI: 10.1099/jgv.0.000012.
27.
KandaT, FuruseY, OshitaniH, et al.Highly efficient CRISPR-Cas9-mediated cloning and functional characterization of gastric cancer-derived Epstein–Barr virus strains. J Virol, 2016; 90:4383–4393. DOI: 10.1128/JVI.00060-16.
28.
LouisCU, StraathofK, BollardCM, et al.Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother, 2010; 33:983–990. DOI: 10.1097/CJI.0b013e3181f3cbf4.
29.
FangW, ZhangJ, HongS, et al.EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget, 2014; 5:12189–12202. DOI: 10.18632/oncotarget.2608.
30.
SaitoR, AbeH, KunitaA, et al.Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol, 2017; 30:427–439. DOI: 10.1038/modpathol.2016.202.
31.
SuS, ZouZ, ChenF, et al.CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology, 2016; 6:e124955–8. DOI: 10.1080/2162402X.2016.1249558.
KennedyEM, KornepatiAVR, GoldsteinM, et al.Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol, 2014; 88:11965–11972. DOI: 10.1128/JVI.01879-14.
34.
ZhenS, HuaL, TakahashiY, et al.In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR-Cas9. Biochem Biophys Res Commun, 2014; 450:1422–1426. DOI: 10.1016/j.bbrc.2014.07.014.
ZhenS, LuJ, WangL, et al.In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR-Cas9 on cervical cancer cell line. Transl Oncol, 2016; 9:498–504. DOI: 10.1016/j.tranon.2016.10.002.
37.
XueW, ChenS, YinH, et al.CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature, 2014; 514:380–384. DOI: 10.1038/nature13589.
38.
JinC, YuanFL, GuYL, et al.Over-expression of ASIC1a promotes proliferation via activation of the beta-catenin/LEF-TCF axis and is associated with disease outcome in liver cancer. Oncotarget, 2017; 8:25977–25988. DOI: 10.18632/oncotarget.10774.
39.
PottLL, HagemannS, ReisH, et al.Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC. Oncotarget, 2017; 8:11950–11962. DOI: 10.18632/oncotarget.14447.
40.
MoyoB, BloomK, ScottT, et al.Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res, 2017 Jan 10 [Epub ahead of print]; DOI:10.1016/j.virusres.2017.01.003.
41.
PankowiczFP, JarrettKE, LagorWR, et al.CRISPR-Cas9: at the cutting edge of hepatology. Gut, 2016; 66:1329–1340. DOI: 10.1136/gutjnl-2016-313565.
42.
SeegerC, SohnJA. Targeting hepatitis B virus with CRISPR-Cas9. Mol Ther Nucleic Acids, 2014; 3:e21–6. DOI: 10.1038/mtna.2014.68.
43.
LiH, ShengC, WangS, et al.Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol, 2017; 7:9–1. DOI: 10.3389/fcimb.2017.00091.
44.
RamananV, ShlomaiA, CoxDBT, et al.CRISPR-Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep, 2015; 5:1083–3. DOI: 10.1038/srep10833.
45.
KarimovaM, BeschornerN, DammermannW, et al.CRISPR-Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep, 2015; 5:1373–4. DOI: 10.1038/srep13734.
46.
LiH, ShengC, LiuH, et al.An effective molecular target site in hepatitis B virus S gene for Cas9 cleavage and mutational inactivation. Int J Biol Sci, 2016; 12:1104–1113. DOI: 10.7150/ijbs.16064.
47.
ZhenS, HuaL, LiuYH, et al.Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther, 2015; 22:404–412. DOI: 10.1038/gt.2015.2.
48.
SakumaT, MasakiK, Abe‐ChayamaH, et al.Highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors for inactivation of hepatitis B virus. Genes Cells, 2016; 21:1253–1262. DOI: 10.1111/gtc.12437.
49.
SampsonTR, SarojSD, LlewellynAC, et al.A CRISPR/Cas system mediates bacterial innate immune evasion and virulence. Nature, 2013; 497:254–257. DOI: 10.1038/nature12048.
50.
PriceAA, SampsonTR, RatnerHK, et al.Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci U S A, 2015; 112:6164–6169. DOI: 10.1073/pnas.1422340112.
51.
AbudayyehOO, GootenbergJS, EssletzbichlerP, et al.RNA targeting with CRISPR-Cas13. Nature, 2017; 550:280–284. DOI: 10.1038/nature24049.
52.
ChenY, ChengG, MahatoRI. RNAi for Treating Hepatitis B Viral Infection. Pharm Res, 2008; 25:72–86. DOI: 10.1007/s11095-007-9504-0.
53.
ElyA, ArbuthnotP. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med, 2015; 20:137–143.
54.
LinY, CradickTJ, BrownMT, et al.CRISPR-Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res, 2014; 42:7473–7485. DOI: 10.1093/nar/gku402.
55.
SchaeferKA, WuWH, ColganDF, et al.Unexpected mutations after CRISPR–Cas9 editing in vivo. Nat Methods, 2017; 14:547–548. DOI: 10.1038/nmeth.4293.
56.
WilsonCJ, FennellT, BothmerA, et al.The experimental design and data interpretation in “Unexpected mutations after CRISPR–Cas9 editing in vivo” by Schaefer et al. are insufficient to support the conclusions drawn by the authors. bioRxiv 2017:153338. DOI: https://doi.org/10.1101/153338.
Cebrian-SerranoA, DaviesB. CRISPR-Cas9 orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools. Mamm Genome, 2017; 28:247–261. DOI: 10.1007/s00335-017-9697-4.
60.
YinH, SongCQ, DorkinJR, et al.Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol, 2016; 34:328–333. DOI: 10.1038/nbt.3471.
61.
MaoZ, BozzellaM, SeluanovA, et al.DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle, 2008; 7:2902–2906. DOI: 10.4161/cc.7.18.6679.
62.
LinS, StaahlBT, AllaRK, et al.Enhanced homology-directed human genome engineering by controlled timing of CRISPR-Cas9 delivery. elife, 2014; 3:e0476–6. DOI: 10.7554/eLife.04766.
